Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
Subscribe To Our Newsletter & Stay Updated
